Evaxion Biotech reports Q2 EPS (21c), two estimates (21c)

Based on the company’s current cash position, with a cash runway until December 2023, further funding is required, to mitigate the company’s ability to continue as a going concern, the company said in a statement. “At Evaxion, we believe that AI-powered, personalized cancer vaccines have the potential to transform the care of patients with melanoma and other cancers. Early-stage clinical data reported at AACR 2023 and ASCO23 indicated that patients treated with our vaccines, EVX-01 or EVX-02, in combination with a checkpoint inhibitor, experienced a treatment benefit, with good overall tolerability” said Per Norlen, CEO of Evaxion. “These data support the potential clinical utility for personalized cancer immunotherapy and the opportunity to advance our next-generation, DNA-based candidate, EVX-03, towards clinical trials in cancer patients.”